Thermo Fisher Scientific (TMO)
675.96
-18.06 (-2.60%)
NYSE · Last Trade: Oct 22nd, 1:42 PM EDT
Detailed Quote
| Previous Close | 694.02 |
|---|---|
| Open | 691.70 |
| Bid | 675.70 |
| Ask | 676.28 |
| Day's Range | 674.10 - 703.20 |
| 52 Week Range | 435.27 - 705.78 |
| Volume | 1,771,214 |
| Market Cap | 265.94B |
| PE Ratio (TTM) | 49.13 |
| EPS (TTM) | 13.8 |
| Dividend & Yield | 1.880 (0.28%) |
| 1 Month Average Volume | 2,354,799 |
Chart
About Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific is a global leader in providing scientific instruments, reagents, and consumables, with a focus on advancing healthcare, life sciences, and laboratory workflows. The company supports a diverse range of customers, including researchers, clinical laboratories, and pharmaceutical companies, by offering innovative solutions that enable breakthroughs in areas such as diagnostics, drug development, and environmental analysis. With a commitment to quality and efficiency, Thermo Fisher Scientific plays a crucial role in enhancing productivity and scientific discovery across various disciplines while promoting better health outcomes worldwide. Read More
News & Press Releases
Life sciences company Thermo Fisher (NYSE:TMO) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $12.14...
Via StockStory · October 22, 2026
Strategic acquisitions are deepening customer relationships while AI integration boosts lab productivity, positioning the company for durable margin expansion.
Via The Motley Fool · October 21, 2026
Adjusted EPS surged 15% as revenue hit $12.14 billion.
Via The Motley Fool · October 21, 2026
Thermo Fisher Scientific (NYSE:TMO) Posts Q3 Earnings Beat With In-Line Revenuechartmill.com
Via Chartmill · October 21, 2026
Thermo Fisher Scientific (NYSE:TMO) Shows Strong Technical Breakout Setupchartmill.com
Via Chartmill · September 7, 2026
Thermo Fisher Scientific (NYSE:TMO) reported third-quarter revenue growth of 9% to $12.14 billion, supported by 6% organic growth, acquisitions and foreign-exchange effects. Adjusted earnings per share rose 15% to $6.68, while adjusted operating income increased 15% to $2.97 billion.
Chairman and C
Via MarketBeat · October 21, 2026
S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declineschartmill.com
Via Chartmill · October 21, 2026
Life sciences company Thermo Fisher (NYSE:TMO) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $12.14...
Via StockStory · October 21, 2026
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2026.
By Thermo Fisher Scientific Inc. · Via Business Wire · October 21, 2026
Life sciences company Thermo Fisher (NYSE:TMO) will be reporting results this Wednesday before the bell. Here’s what investors should know. Thermo Fisher bea...
Via StockStory · October 19, 2026
Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial.
Via MarketBeat · October 14, 2026
Which S&P500 stocks are gapping on Thursday?chartmill.com
Via Chartmill · October 8, 2026
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before the market opens on Wednesday, October 21, 2026, and will hold a conference call on the same day at 7:00 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations.
By Thermo Fisher Scientific Inc. · Via Business Wire · September 28, 2026
Thermo Fisher Scientific, the world leader in serving science, today announced the Gibco™ CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support strong cell growth and protein production across CHO-K1 cell lines. Available in liquid and dry powder media (DPM) formats, the panel can offer flexible options for process development, scale-up, and manufacturing.
By Thermo Fisher Scientific Inc. · Via Business Wire · September 23, 2026
Thermo Fisher’s 36.4% return over the past six months has outpaced the S&P 500 by 20.1%, and its stock price has climbed to $652.30 per share. This was partl...
Via StockStory · September 21, 2026
Thermo Fisher Scientific (NYSE:TMO) Chairman and Chief Executive Officer Marc Casper said the company is seeing improving demand across several end markets and expects 2026 to be an “outstanding year,” supported by stronger customer activity and operational execution.
Speaking at Morgan Stanley’s G
Via MarketBeat · September 17, 2026
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 15 years by 4.35% on an annualized basis producing an average annual return of 17.57%. Currently, Thermo Fisher Scientific has a market
Via Benzinga · September 8, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Via StockStory · September 4, 2026
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 9:15 a.m. (ET).
By Thermo Fisher Scientific Inc. · Via Business Wire · September 1, 2026
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 10 years by 1.87% on an annualized basis producing an average annual return of 15.26%. Currently, Thermo Fisher Scientific has a market
Via Benzinga · August 26, 2026
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Via StockStory · August 26, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how research tools & consu...
Via StockStory · August 18, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via StockStory · August 18, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via StockStory · August 13, 2026
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.
By Thermo Fisher Scientific Inc. · Via Business Wire · August 12, 2026